The best endovascular therapy for calcified femoropopliteal artery disease with interwoven nitinol stent backup strategy

The best endovascular therapy for calcified femoropopliteal artery disease with interwoven nitinol stent backup strategy - BURDOCK study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035331

Enrollment

300

Registered

2019-01-07

Start date

2019-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic peripheral arterial disease with calcified superficial femoral artery occluded /stenotic lesion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Age older than 20 2)PAOD Rutherford Category 2-5 3)ABI lower than 0.9 4)Atheroscleritic lesion by DUS,CTA or MRA 5)calcified lesion

Exclusion criteria

Exclusion criteria: 1)common femoral artery lesion 2)thrombotic lesion 3)anastasis of bypass graft

Design outcomes

Primary

Measure	Time frame
Binary restenosis rate at 1 year	—

Secondary

Measure	Time frame
1)All cause mortality 2)Clinical driven Target vessel revascularization 3)Conversion rate of bypass surgery 4)Acute limb ischemia 5)Major limb amputation rate 6)MALE 7)Presise stent implantation 8)restenosis rate at 2Y	—

Countries

Japan

Contacts

Public ContactMasahiko FUJIHARA

Kishiwada Tokushukai Hospital Cardiology

masahikofujihara@yahoo.co.jp0724459915

Outcome results